# | Filing Date | Period End Date | Type | Report Link |
---|---|---|---|---|
No Data found |
# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
HC Wainwright & Co. analyst Swayampakula Ramakanth reiterates Evaxion Biotech (NASDAQ:EVAX) with a Buy and maintains $14...
Ladenburg Thalmann analyst Ahu Demir upgrades Evaxion Biotech (NASDAQ:EVAX) from Neutral to Buy and announces $8 price target.
Evaxion Biotech (NASDAQ:EVAX) reported quarterly losses of $(0.16) per share which beat the analyst consensus estimate of $(1.6...
HC Wainwright & Co. analyst Swayampakula Ramakanth reiterates Evaxion Biotech (NASDAQ:EVAX) with a Buy and maintains $14...